Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2012, 4(1), 193-217; doi:10.3390/cancers4010193
Review

Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer

1
, 2
, 3
, 2
, 3
 and 2,*
Received: 13 January 2012; in revised form: 14 February 2012 / Accepted: 16 February 2012 / Published: 22 February 2012
(This article belongs to the Special Issue Immune Responses to Human Prostate Cancer)
View Full-Text   |   Download PDF [243 KB, uploaded 22 February 2012]
Abstract: Prostate cancer (PCa) is the most common noncutaneous cancer diagnosis and the second leading cause of cancer-related deaths among men in the United States. Effective treatment modalities for advanced metastatic PCa are limited. Immunotherapeutic strategies based on T cells and antibodies represent interesting approaches to prevent progression from localized to advanced PCa and to improve survival outcomes for patients with advanced disease. CD8+ cytotoxic T lymphocytes (CTLs) efficiently recognize and destroy tumor cells. CD4+ T cells augment the antigen-presenting capacity of dendritic cells and promote the expansion of tumor-reactive CTLs. Antibodies mediate their antitumor effects via antibody-dependent cellular cytotoxicity, activation of the complement system, improving the uptake of coated tumor cells by phagocytes, and the functional interference of biological pathways essential for tumor growth. Consequently, several tumor-associated antigens (TAAs) have been identified that represent promising targets for T cell- or antibody-based immunotherapy. These TAAs comprise proteins preferentially expressed in normal and malignant prostate tissues and molecules which are not predominantly restricted to the prostate, but are overexpressed in various tumor entities including PCa. Clinical trials provide evidence that specific immunotherapeutic strategies using such TAAs represent safe and feasible concepts for the induction of immunological and clinical responses in PCa patients. However, further improvement of the current approaches is required which may be achieved by combining T cell- and/or antibody-based strategies with radio-, hormone-, chemo- or antiangiogenic therapy.
Keywords: antibodies; dendritic cells; immunotherapy; prostate cancer; T cells antibodies; dendritic cells; immunotherapy; prostate cancer; T cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Kiessling, A.; Wehner, R.; Füssel, S.; Bachmann, M.; Wirth, M.P.; Schmitz, M. Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer. Cancers 2012, 4, 193-217.

AMA Style

Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M. Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer. Cancers. 2012; 4(1):193-217.

Chicago/Turabian Style

Kiessling, Andrea; Wehner, Rebekka; Füssel, Susanne; Bachmann, Michael; Wirth, Manfred P.; Schmitz, Marc. 2012. "Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer." Cancers 4, no. 1: 193-217.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert